Evaluation of Safety and Effectiveness on Oral Anticoagulants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

12354 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-21

Study Completion Date

2020-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to compare the risk of major bleeding among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

NCT03087487

Non-Valvular Atrial Fibrillation

COMPLETED

Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure

NCT03508271

Atrial Fibrillation Heart Failure

COMPLETED

Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation

NCT03570047

Non-valvular Atrial Fibrillation

COMPLETED

Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation

NCT02919982

Nonvalvular Atrial Fibrillation

COMPLETED

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

NCT04681482

Atrial Fibrillation Obesity Anticoagulants

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient initiating warfarin

Non-Interventional

Intervention Type OTHER

Non-Interventional

Patient initiating apixaban

Non-Interventional

Intervention Type OTHER

Non-Interventional

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Interventional

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals greater than or equal to 20 years old as of the index date
* At least 1 diagnosis of NVAF prior to or on index date, identified by any medical records
* Newly treated with warfarin or apixaban between 01-Jan-2011 to 31-Dec-2016. The first warfarin or apixaban prescription date during the identification period will be designated as the index date

Exclusion Criteria

* Patient's medical records indicating pregnancy during the follow-up period
* Patient's medical records indicating taking warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban during the 6-months prior to the index date
* Had \> 1 OAC prescription in the patient's medical records on the index date

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No